Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Diabetes Obes Metab
; 25(7): 1865-1873, 2023 07.
Article
in En
| MEDLINE
| ID: mdl-36872067
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2 Inhibitors
Type of study:
Clinical_trials
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Diabetes Obes Metab
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2023
Document type:
Article
Affiliation country:
Corea del Sur
Country of publication:
Reino Unido